AR882 is an investigational selective uric acid transporter 1 inhibitor. The Food and Drug Administration (FDA) has granted Fast Track designation to AR882 for the treatment of clinically visible ...
In a phase 2b trial, nearly 100% of patients treated with SAP-001 at the 30mg and 60mg doses achieved the target serum uric acid level of less than 6mg/dL. The Food and Drug Administration (FDA) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results